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Abstract     
Synthesis of paramagnetically modified deprenyl and oxotremorine is reported. Starting from 5- 
and 6-membered 2,5-disubstituted nitrones (1, 6) or 4-phenyl-2,5,5-trimethyl-1H-pyrroline 1-
oxide (11) deprenyl or oxotremorine like nitroxides were synthesized via Grignard reactions. The 
corresponding pre-nitroxides with propargylamine structure were achieved by reduction of 
nitroxides followed by methylation.  
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Introduction    
 
Parkinson’s disease is an age-related disorder that afflicts as many as 2% of all individuals.1 The 
biochemical basis for the motor symptoms of Parkinson’s disease is a loss of dopamine.2, 3 
Therefore Parkinson’s disease can be relieved by treating patients with L-3,4-
dihydroxyphenylalanine (L-DOPA) and an inhibitor of peripheral L-DOPA decarboxylase. In 
order to preserve brain dopamine, it is also common to treat patients with a monoamine oxidase 
B (MAO-B) inhibitor.4 Selegiline (L-Deprenyl) and Rasagiline (Figure 1)5-10 are selective 
inhibitors of MAO-B and Selegiline is currently used for the treatment of Parkinson’s and 
Alzheimer’s diseases. This compound was reported to have a neuroprotective activity due to the 
prevention of apoptosis.11 The propargylamine pharmacophore of Selegiline and Rasagiline 
appears to be responsible for neuroprotective activity. Crystallographic analysis revealed that 
rasagiline covalently binds with its propargyl group to flavine enzyme to form an iminopropene 
chain.12 
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Figure 1 
Namiecinski et al. found that nitroxides with propargylamine chain such as JSAK-648 (Figure 1) 
can cross the blood-brain barrier and have been shown to have antioxidant properties, cell 
protection against oxidative stress and Reactive Oxygen Species (ROS) cytotoxicity.13,14 It is 
important to have a radical scavenger in statu nascendi to prevent damages caused by ROS, 
because the MAO-B mediated metabolism of dopamine and its autooxidation generate O2.-, H2O2 
and the highly toxic .OH in the presence of trace levels of free iron ions. 
Continuing our research in the synthesis of experimental drugs with dual activity containing 
nitroxide or its precursor,15-19 we wish to extend this idea for neuroprotective drugs such as 
Deprenyl and Oxotremorine. Oxotremorine (Figure 1) is known as a muscarinic agonist and is 
also used in the Alzheimer’s therapy. Therefore a large number of Oxotremorine derivatives 
were reported and investigated.20-22 
The metabolic oxidation of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to the 
oxidation product MPDP+ is also catalyzed by MAO-B. Following a second two-electron 
oxidation, the ultimate neurotoxic metabolite, 1-methyl-4-phenylpyridinium (MPP+) is 
generated.23,24 MPP+ is a mitochondrial toxin, which selectively damages nigrostriatal neurons 
and induces Parkinsonian syndrome in humans.25 Several other allylamines act as good MAO-B 
substrates, such as the 5-membered ring analogue of MPTP.23 (Figure 2) 
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Motivated by these findings the synthesis of Deprenyl and Oxotremorine derivatives with 5- or 
6-membered nitroxide rings was planned. We desired to investigate the oxidation of their 
sterically hindered secondary or tertiary amine precursors and a six membered model compound. 
We hope that these compounds will act as MAO-B antagonists or muscarinic agonists and as 
antioxidant compounds in the central nervous system (CNS). 
 
 
Results and Discussion    
 
An evident approach for the combination of Deprenyl and Oxotremorine structure with 
nitroxides was the reaction of five- or six-memberd nitrones and properly chosen Grignard-
reagents, supporting the introduction of the required aryl or alkynyl group easily (Figure 3). 
 
 
Figure 3 
 
Treatment of 2,5-dimethyl-3,4-dihydro-2H-pyrrole 1-oxide (1) or 2,6-dimethyl-2,3,4,5-
tetrahydro-pyridine 1-oxide (6) with benzylmagnesium chloride in dry Et2O followed by the 
oxidation of N-hydroxy compound with activated MnO2 afforded the appropriate nitrones (2, 7). 
The reaction of ethynylmagnesium bromide with 2-benzyl substituted nitrones 2 and 7 in THF 
yielded the stereoisomers of nitroxide 3 and 8, respectively. The ratio of trans/cis isomers was 
approximately 5:1. For further reactions the trans isomers were used. Complete assignments of 
compound 3 could be obtained with conventional 1D and 2D NMR spectroscopy methods after 
the treatment of the free radical compound with diphenylhydrazine in CDCl3. 
The Grignard reaction of nitrone 11 with ethynylmagnesium bromide yielded 3-phenyl-5-ethynyl 
substituted nitroxide 12. In the latter case the spacer between the nitrogen and aryl group is more 
rigid, being a part of a five-membered ring. To get more Deprenyl-like nitroxides 3, 8 and 12 
were reduced to secondary amines by treating them with 5 equiv Fe powder in glacial acetic acid 
at 60°C producing amines 4, 9 and 13. These secondary amines were alkylated by refluxing them 
with methyl iodide excess in THF affording tertiary amines 5, 10 and 14 (Scheme 1). The 
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advantages of synthesized secondary and tertiary amines beyond the structural fidelity are their 
better water solubility and oxygen scavenging ability such detoxyfying ROS during non-toxic, 
stable nitroxide free radical formation. 
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Scheme 1 Reagents and conditions: (a) Benzylmagnesium chloride (1.2 equiv.), Et2O, 0 °C → 
r.t., 3 h, aq. sat. NH4Cl, then CHCl3, MnO2 (cat.), O2, r.t., 1 h (62-74 %). (b) HC≡CMgBr, THF, 0 
°C → r.t., 2 h, aq. sat. NH4Cl, then CHCl3, MnO2 (cat.), O2, r.t., 30 min (65-77 %). (c) AcOH, Fe 
powder (5 equiv.), 60 °C, 1 h, then H2O, K2CO3 (57-68 %). (d) MeI, THF, reflux, 1 h (65-83 %). 
(e) H2O2 (2 equiv), Na2WO4 (cat.), MeOH, r.t., 24 h (35-42 %) 
 
The oxidation of both 5- and 6-membered sterically hindered tertiary amines was investigated in 
MeOH with H2O2. However, in case of compound 14 or model compound 1526 upon oxidation 
nitroxides 12 and 1627 were formed and because of tetramethyl group no MPP+-like product is 
possible even at harsh oxidation conditions. 
 
For Oxotremorine analogue synthesis we prepared compound 17 from nitrone 11 and a 
Grignard-reagent generated from propargylic alcohol with 2 equiv. EtMgBr in situ. After the 
oxidation of hydroxylamine with catalytic amount MnO2 17 propargylic alcohol was converted 
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to 18 bromo compound by treating mesylate with LiBr in acetone.  This bromo compound was 
used to alkylate pyrrolidine or 2-pyrrolidinone to yield spin labelled tremorine (19) or 
oxotremorine (20) derivatives. Nitroxides (19 and 20) were reduced to sterically hindered 
secondary amines (21, 22) with Fe powder in AcOH as mentioned above.  
To avoid the quaternary salt formation of tertiary amine of compounds 21 and 22 the N-
methylation of secondary amines by refluxing with formaldehyde in the presence of formic acid, 
(Eschweiler-Clark conditions)21 furnished the tertiary pyrrolidine derivatives 23 and 24 (Scheme 
2). 
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Scheme 2 Reagents and conditions: (a) BrMgC≡C-CH2-OMgBr (1.1 equiv.), THF, 0 °C → r.t., 
12 h, aq. sat. NH4Cl, then CHCl3, MnO2 (cat.), O2, r.t., 1 h (58 %). (b) Et3N, CH2Cl2, CH3SO2Cl, 
0 °C → r.t., 30 min, then acetone, LiBr (2 equiv.), reflux, 30 min (83 %). (c) pyrrolidine (2 
equiv.), THF, reflux, 1 h (88 % for 19); NaH, THF/DMF, 2-pyrrolidinone, r.t., 2.5 h (74 % for 
20). (d) AcOH, Fe powder (5 equiv.), 60 °C, 1 h then H2O, K2CO3 (53-71 %). (e) HCHO (37 %, 
10 equiv.), HCOOH (88 %, 10 equiv.), reflux, 6 h, then K2CO3 (69-78 %).  
 
Conclusions    
 
In conclusion, starting from disubstituted or trisubstituted five- or six-membered nitrones 
paramagnetic Deprenyl and Oxotremorine analogues were synthesized by means of Grignard 
reactions. Reduction of nitroxides and N-methylation offered a closer analogue of Deprenyl and 
Oxotremorine neuroprotective drugs with ROS scavenging structural elements, such as sterically 
hindered amine (pre nitroxide) compounds. The biological study of these compounds is in 
progress and will be reported in due course. 
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Experimental Section     
 
Melting points were determined with a Boetius micro melting point apparatus and are 
uncorrected. Elemental analyses (C, H, N, S) were performed on Fisons EA 1110 CHNS 
elemental analyzer. The IR (Specord 85) spectra were in each case consistent with the assigned 
structure. Mass spectra were recorded on a Thermoquest Automass Multi and VG TRIO-2 
instruments in the EI mode. 1H NMR spectra were recorded with Varian UNITYINOVA 400 WB 
spectrometer. Chemical shifts are referenced to Me4Si. Measurements were run at 298 K probe 
temperature in CDCl3 solution. ESR spectra were taken on Miniscope MS 200 in 10-4 M CHCl3 
solution and all monoradicals gave triplett spectrum aN = 14.7-16.5 G. Flash column 
chromatography was performed on Merck Kieselgel 60 (0.040-0.063 mm). Qualitative TLC was 
carried out on commercially available plates (20 x 20 x 0.02 cm) coated with Merck Kieselgel 
GF254.  
 
Synthesis of 2-benzyl-nitrones (2, 7); General procedure exemplified by 2-benzyl-2,5-
dimethyl-3,4-dihydro-2H-pyrrole 1-oxide (2) 
To a solution of benzylmagnesium chloride (prepared from benzyl-chloride (7.62 g, 0.06 mol) 
and Mg (1.50 g, 0.06 mol)) in dry Et2O (50 mL) nitrone (1) (5.65 g, 0.05 mol) in dry Et2O (50 
mL) was added dropwise at 0 °C. The reaction mixture was stirred at r.t. for 3 h, then aq. sat. 
NH4Cl (80 mL) was added. The organic layer was separated and the aqueous layer was extracted 
with CHCl3 (3 x 30 mL). The combined organic layer was dried (MgSO4) and evaporated. The 
residue was dissolved in CHCl3 (50 mL), activated MnO2 (cat., 100 mg) was added and the 
mixture was bubbled with O2 for 1 h at r.t. The reaction mixture was then filtered, evaporated 
and purified by flash column chromatography with CHCl3/MeOH to give 2-benzyl-nitrone. 
2-Benzyl-2,5-dimethyl-3,4-dihydro-2H-pyrrole 1-oxide (2): 7.51 g (74 %); oil; Rf = 0.35 (CHCl3-
Et2O-MeOH 4:1.5:0.5); Anal. calcd. for C13H17NO (203.28): C 76.81 %, H 8.43 %, N 6.89 %; 
found: C 76.99 %, H 8.35 %, N 6.82 %. MS (EI) m/z (rel. int. %): 203 (M+, 63), 131 (58), 112 
(80), 91 (100). 
2-Benzyl-2,6-dimethyl-2,3,4,5-tetrahydro-pyridine 1-oxide (7): 6.73 g (62 %); oil; Rf =  0.41 
(CHCl3-Et2O-MeOH 4:1.5:0.5); Anal. calcd. for C14H19NO (217.31): C 77.38 %, H 8.81 %, N 
6.45 %; found: C 77.33 %, H 8.90 %, N 6.32 %. MS (EI) m/z (rel. int. %): 217 (M+, 10), 152 
(30), 129 (37), 91 (100), 73 (96), 41 (84). 
 
Synthesis of 5- and 6-ethynyl-nitroxides (3, 8, 12); General procedure exemplified by cis- 
and trans-2-benzyl-5-ethynyl-2,5-dimethyl-pyrrolidine-1-yloxyl radical (3) 
To ethynylmagnesium bromide (0.5 M sol. in THF, 50 mL) a solution of nitrone (2) (4.06 g, 0.02 
mol) in dry THF (30 mL) was added dropwise at 0 °C. The mixture was stirred at r.t. for 2 h then 
aq. sat. NH4Cl (40 mL) was added. The organic layer was separated and the aqueous layer was 
extracted with CHCl3 (3 x 20 mL). The combined organic layer was dried (MgSO4) and 
evaporated. The residue was dissolved in CHCl3 (50 mL), activated MnO2 (cat., 100 mg) was 
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added and the mixture was bubbled with O2 for 30 min at r.t. The reaction mixture was then 
filtered, evaporated and purified by flash column chromatography with hex hexane/Et2O to give 
the cis and trans stereoisomers of nitroxide. 
Trans-2-benzyl-5-ethynyl-2,5-dimethyl-pyrrolidine-1-yloxyl Radical (trans-3): 2.78 g (61 %); oil; 
Rf = 0.64 (hexane-EtOAc 2:1); Anal. calcd. for C15H18NO (228.31): C 78.91 %, H 7.95 %, N 
6.13 %; found: C 78.89 %, H 7.82 %, N 6.31 %. MS (EI) m/z  (rel. int. %): 228 (M+, 22), 183 
(5), 132 (17), 117 (95), 91 (100). 1H NMR (CDCl3 + diphenyl-hydrazine) δ (ppm): 2.78 (d, 
J=12.5 Hz, 1H, Ph-CH2), 2.70 (d, J=12.5 Hz, 1H, Ph-CH2), 2.47 (s, 1H, -C≡CH), 1.97 (m, 1H, 
3b-CH2), 1.83 (m, 2H, 4-CH2), 1.47 (s, 3H, 2-CH3, 1,40 (m, 1H, 3a-CH2), 1.33 (s, 3H, 5-CH3). 
Cis-2-benzyl-5-ethynyl-2,5-dimethyl-pyrrolidine-1-yloxyl Radical (cis-3): 730 mg (16 %); oil; Rf 
= 0.57 (hexane-EtOAc 2:1); Anal. calcd. for C15H18NO (228.31): C 78.91 %, H 7.95 %, N 6.13 
%; found: C 78.72 %, H 7.89 %, N 6.24 %. MS (EI) m/z (rel. int. %): 228 (M+, 12), 183 (5), 132 
(18), 117 (59), 91 (100). 1H NMR (CDCl3 + diphenyl-hydrazine) δ (ppm): 3.24 (d, J=12.3 Hz, 
1H, Ph-CH2), 3.02 (d, J=12.3 Hz, 1H, Ph-CH2), 2.53 (s, 1H, -C≡CH), 2.24 (m, 1H, 3b-CH2), 
2.12  (m, 1H, 4b-CH2), 1.82 (m, 1H, 3a-CH2), 1.56 (s, 3H, 2-CH3), 1.36 (m, 1H, 4a-CH2), 1.19 
(s, 3H, 5-CH3). To determine the orientation of the different groups in the molecule the NOESY 
experiment was used. The cross peaks within H (3a):2-CH3 and 2-CH3:5-CH3 suggest, that these 
groups are on the same side of the pyrrolidine ring. 
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Trans-2-benzyl-6-ethynyl-2,6-dimethyl-piperidine-1-yloxyl Radical (trans-8): 2.66 g (55 %); 
thick oil; Rf = 0.66 (hexane-EtOAc 2:1); Anal. calcd. for C16H20NO (242.34): C 79.30 %, H 8.32 
%, N 5.78 %; found: C 79.27 %, H 8.50 %, N 5.77 %. MS (EI) m/z (rel. int. %): 242 (M+, 26), 
152 (9), 117 (22), 91 (100). 
Cis-2-benzyl-6-ethynyl-2,6-dimethyl-piperidine-1-yloxyl Radical (cis-8): 485 mg (10 %); oil; Rf 
= 0.62 (hexane-EtOAc 2:1); Anal. calcd. for C16H20NO (242.34): C 79.30 %, H 8.32 %, N 5.78 
%; found: C 79.36 %, H 8.17 %, N 5.63 %. MS (EI) m/z (rel. int. %): 242 (M+, 35), 152 (51), 
117 (39), 91 (100). 
Trans-5-ethynyl-2,2,5-trimethyl-3-phenyl-pyrrolidine-1-yloxyl Radical (trans-12): 2.74 g (60 %); 
mp 82-84 °C; Rf = 0.55 (hexane-EtOAc 2:1); Anal. calcd. for C15H18NO (228.31): C 78.91 %, H 
7.95 %, N 6.13 %; found: C 78.89 %, H 8.01 %, N 6.10 %. MS (EI) m/z (rel. int. %): 228 (M+, 
3), 183 (6), 132 (61), 117 (100), 91 (72). 
Cis-5-ethynyl-2,2,5-trimethyl-3-phenyl-pyrrolidine-1-yloxyl Radical (cis-12): 502 mg (11 %); mp 
140-141 °C; Rf = 0.51 (hexane-EtOAc 2:1); Anal. calcd. for C15H18NO (228.31): C 78.91 %, H 
7.95 %, N 6.13 %; found: C 78.77 %, H 7.81 %, N 5.96 %. MS (EI) m/z (rel. int. %): 228 (M+, 
4), 183 (5), 132 (61), 117 (100), 91 (73). 
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Synthesis of 5-(3-hydroxy-prop-1-ynyl)-2,2,5-trimethyl-3-phenyl-pyrrolidin-1-yloxyl radical 
(17) 
To a stirred solution of propargyl magnesium bromide (0.022 mol) (prepared from propargyl 
alcohol and 2 equiv. of ethyl magnesium bromide) in THF (50 mL) was added dropwise a 
solution of nitrone 11 (4.06 g, 0.02 mol) in THF (20 mL) at 0 °C. After stirring the mixture at r.t. 
for 12 h sat. aq. NH4Cl (50 mL) was added. The organic phase was separated, and the aqueous 
layer was extracted with CHCl3. The combined organic layer was dried (MgSO4) and evaporated. 
The residue was dissolved in CHCl3 (20 mL), activated MnO2 (cat. 100 mg) was added and O2 
was bubbled for 1 h at r.t. The mixture was filtered, evaporated and purified by flash column 
chromatography using hexane/EtOAc to give nitroxide 17, 2.99 g (58 %); oil; Rf = 0.19 (CHCl3-
Et2O 2:1); Anal. calcd. for C16H20NO2 (258.34): C 74.39 %, H 7.80 %, N 5.42 %; found: C 74.28 
%, H 7.85 %, N 5.36 %. MS (EI) m/z (rel. int. %): 258 (M+, 4), 243 (15), 131 (17), 124 (57), 42 
(100). 
 
Synthesis of 5-(3-bromo-prop-1-ynyl)-2,2,5-trimethyl-3-phenyl-pyrrolidin-1-yloxyl radical 
(18) 
To a stirred solution of nitroxide propargyl alcohol 17 (2.58 g, 0.01 mol) and Et3N (1.11 g, 1.10 
mol) in anhyd. CH2Cl2 (40 mL) CH3SO2Cl (1.26 g, 1.10 mol) was added dropwise at 0 °C. The 
reaction mixture was stirred at r.t. for 30 min then the solvent was evaporated. The residue was 
dissolved in acetone (20 mL), LiBr (1.74 g, 0.02 mol) was added and refluxed for 30 min. 
Acetone was then evaporated, the residue was dissolved in Et2O, washed with sat. aq. NaCl, 
dried (MgSO4) and evaporated. Propargyl bromide 18 was purified by flash column 
chromatography using hexane/Et2O to yield: 2.66 g (83 %); mp 61-63 °C; Rf = 0.78 (hexane-
EtOAc 2:1); Anal. calcd. for C16H19BrNO (321.23): C 59.82 %, H 5.96 %, N 4.36 %, Br 24.87 
%; found: C 59.88 %, H 5.89 %, N 4.23 %, Br 24.72 %. MS (EI) m/z (rel. int. %): 322/320 (M+, 
16/16), 247/249 (15/15), 211 (32), 132 (100), 117 (95). 
 
Synthesis of 2,2,5-trimethyl-3-phenyl-5-(3-pyrrolidin-1-yl-prop-1-ynyl)-pyrrolidin-1-yloxyl 
radical (19) 
To a solution of propargyl bromide 18 (2.57 g, 8.0 mmol) in dry THF (30 mL) pyrrolidine (1.14 
g, 16 mmol) was added and the reaction mixture was boiled for 1 h. The organic phase was 
washed with aq. sat. NaCl, dried and purified by flash column chromatography with CHCl3/Et2O 
to yield pyrrolidine 19, 2.19 g (88 %); oil; Rf = 0.19 (CHCl3-Et2O 2:1); Anal. calcd. for 
C20H27N2O (311.44): C 77.13 %, H 8.74 %, N 8.99 %; found: C 77.28 %, H 8.92 %, N 9.04 %. 
MS (EI) m/z (rel. int. %): 311 (M+, 33), 296 (10), 108 (98), 84 (100). 
 
Synthesis of 1-[3-(1-oxyl-2,5,5-trimethyl-4-phenyl-pyrrolidin-2-yl)-prop-2-ynyl]-pyrrolidin-
2-one radical (20) 
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To a suspension of NaH (72 mg, 3 mmol) in dry THF (10 mL) DMF (3 mL) and 2-pyrrolidinone 
(255 mg, 3 mmol) were added. The reaction mixture was stirred for 30 min then bromide 18 (963 
mg, 3 mmol) was added dropwise in dry THF (10 mL). After stirring for 2 h, sat. aq. NaCl was 
added (10 mL). The organic phase was separated, dried (MgSO4) and evaporated. The resulting 
product was purified by flash chromatography to give 20 as yellow crystals: 722 mg (74 %); mp: 
110-112 °C; Rf = 0.21 (CHCl3-Et2O 2:1); Anal. calcd. for C20H25N2O2 (325.43): C 73.82 %, H 
7.74 %, N 8.61 %; found: C 73.84 %, H 7.67 %, N 8.52 %. MS (EI) m/z (rel. int. %): 325 (M+, 
20), 311 (11), 280 (16), 210 (17), 195 (30), 164 (57), 132 (100), 98 (78), 91 (58). 
 
Reduction of nitroxides (3, 8, 12, 19, 20) to sterically hindered secondary amines (4, 9, 13, 
21, 22); General procedure exemplified by trans-2-benzyl-5-ethynyl-2,5-dimethyl-
pyrrolidine (4) 
To a solution of nitroxide 3 (1.14 g, 5 mmol) in AcOH (20 mL) Fe powder (1.40 g, 25 mmol) 
was added, the mixture was warmed up to 60 °C and kept at this temperature for 1 h. Then the 
reaction mixture was cooled to r.t., water (30 mL) was added and the solution was alkaline with 
solid K2CO3. The aqueous phase was extracted with CHCl3 (3 x 20 mL). The organic layer was 
dried (MgSO4) and evaporated. The residue was purified by flash column chromatography with 
CHCl3/MeOH to give amine. 
Trans-2-benzyl-5-ethynyl-2,5-dimethyl-pyrrolidine (4): 725 mg (68 %); mp (HCl salt) 218-220 
°C; Rf = 0.61 (CHCl3-Et2O 2:1); Anal. calcd. for HCl salt C15H20NCl (249.78): C 72.13 %, H 
8.07 %, N 5.61 %, Cl 14.19 %; found: C 72.30 %, H 8.21 %, N 5.73 %, Cl 14.25 %. MS (EI) m/z 
(rel. int. %): 213 (M+, 28), 198 (1), 122 (100), 91 (93). 
Trans-2-benzyl-6-ethynyl-2,6-dimethyl-piperidine (9): 648 mg (57 %); mp (HCl salt) 225-227  
°C; Rf = 0.52 (CHCl3-Et2O 2:1); Anal. calcd. for HCl salt C16H22NCl (263.81): C 72.85 %, H 
8.41 %, N 5.31 %, Cl 13.44 %; found: C 72.76 %, H 8.53 %, N 5.39 %, Cl 13.60 %. MS (EI) m/z 
(rel. int. %): 227 (M+, 1), 212 (21), 136 (100), 91 (98), 77 (77), 42 (98). 
Trans-5-ethynyl-2,2,5-trimethyl-3-phenyl-pirrolidine (13): 661 mg (62 %); mp (HCl salt) 
sublimates over 220 °C; Rf = 0.55 (CHCl3-Et2O-MeOH 4:1.5:0.5); Anal. calcd. for HCl salt 
C15H20NCl (249.78): C 72.13 %, H 8.07 %, N 5.61 %, Cl 14.19 %; found: C 72.15 %, H 7.96 %, 
N 5.65 %, Cl 14.22 %. MS (EI) m/z (rel. int. %): 213 (M+, 15), 198 (20), 141 (31), 109 (100), 94 
(65), 42 (28). 
2,2,5-Trimethyl-3-phenyl-5-(3-pyrrolidin-1-yl-prop-1-ynyl)-pyrrolidine (21) 786 mg (53 %); mp 
140-142 °C; Rf = 0.11 (CHCl3-Et2O-MeOH 4:1.5:0.5); Anal. calcd. for C20H28N2 (296.45): C 
81.03 %, H 9.52 %, N 9.45 %; found: C 81.02 %, H 9.55 %, N 9.58 %. MS (EI) m/z (rel. int. %): 
296 (M+, 4), 281 (3), 227 (19), 121 (68), 91 (22), 81 (36), 69 (100). 
1-[3-(2,5,5-trimethyl-4-phenyl-pyrrolidin-2-yl)-prop-2-ynyl]-pyrrolidin-2-one (22) 1.102 g (71 
%); oil; Rf = 0.21 (CHCl3-Et2O-MeOH 4:1.5:0.5); Anal. calcd. for C20H26N2O (310.44): C 77.38 
%, H 8.44 %, N 9.02 %; found: C 77.49 %, H 8.41 %, N 9.08 %. MS (EI) m/z (rel. int. %): 310 
(M+, 1), 295 (2), 206 (13), 98 (58), 42 (100). 
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Alkylation of secondary amines (4, 9, 13) to N-methyl derivatives (5, 10, 14); General 
procedure exemplified by trans-2-benzyl-5-ethynyl-1,2,5-trimethyl-pyrrolidine (5): 
To a solution of amine 4 (213 mg, 1 mmol) in THF (15 mL) MeI (142 mg, 1 mmol) was added 
and the reaction mixture was refluxed for 1 h. The organic phase was extracted with 10 % K2CO3 
solution, dried (MgSO4) and evaporated. The residue was purified by flash chromatography with 
CHCl3/Et2O as eluent to give N-methyl derivative. 
Trans-2-benzyl-5-ethynyl-1,2,5-trimethyl-pyrrolidine (5): 188 mg (83 %); mp (HCl salt) 
sublimates over 185 °C; Rf = 0.85 (CHCl3-Et2O 2:1); Anal. calcd. for HCl salt C16H22NCl 
(263.81): C 72.85 %, H 8.41 %, N 5.31 %, Cl 13.44 %; found: C 72.77 %, H 8.47 %, N 5.20 %, 
Cl 13.49 %. MS (EI) m/z (rel. int. %): 227 (M+, 28), 212 (2), 202 (2), 136 (100), 91 (93). 
Trans-2-benzyl-6-ethynyl-1,2,6-trimethyl-piperidine (10): 157 mg (65 %); mp (HCl salt) 
sublimates over 195 °C; Rf = 0.46 (hexane-EtOAc 2:1); Anal. calcd. for HCl salt C17H24NCl 
(277.84): C 73.49 %, H 8.71 %, N 5.04 %, Cl 12.76 %; found: C 73.55 %, H 8.62%, N 4.97 %, 
Cl 12.61 %. MS (EI) m/z (rel. int. %): MS (EI) m/z (rel. int. %): 241 (M+, 13), 226 (8), 148 
(100), 91 (82). 
Trans-2-ethynyl-1,2,5,5-tetramethyl-4-phenyl-pyrrolidine (14): 163 mg (72 %); mp (HCl salt) 
202-204 °C; Rf = 0.71 (CHCl3-Et2O 2:1); Anal. calcd. for HCl salt C16H22NCl (263.81): C 72.85 
%, H 8.41 %, N 5.31 %, Cl 13.44 %; found: C 72.85 %, H 8.31 %, N 5.27 %, Cl 13.28 %. MS 
(EI) m/z (rel. int. %): 227 (M+, 7), 212 (100), 186 (17), 108 (11), 91 (7), 56 (19). 
 
Oxidation of tertiary amines (14, 15) to nitroxides (12, 16) 
To a solution of tertiary amine 14 (227 mg, 1 mmol) or 15 (229 mg, 1 mmol) in MeOH (5 mL) 
H2O2 (30 % sol. in water, 0.5 mL, 5 mmol) and Na2WO4 (cat, 10 mg) was added at r.t. The 
reaction mixture was allowed to stand for 24 h at this temperature. The solvent was evaporated, 
brine (5 mL) was added and the aqueous phase was extracted with CHCl3 (3 x 5 mL). The 
organic phase was dried (MgSO4), evaporated and purified with flash column chromatography to 
yield nitroxides 12 (96 mg, 42 %) and 16 (80 mg, 35 %). The physical and spectroscopic data of 
these compounds are identical described above. 
 
 
Synthesis of 1,2,2,5-tetramethyl-3-phenyl-5-(3-pyrrolidin-1-yl-prop-1-ynyl)-pyrrolidine (23) 
and 1,2,2,5-tetramethyl-3-phenyl-5-(3-pyrrolidin-1-yl-prop-1-ynyl)-pyrrolidin-2-one (24)  
A mixture of the free base of 21 (296 mg, 1 mmol) or 22 (310 mg, 1 mmol) and 10-fold excess 
each of 37 % formalin and 88 % formic acid was heated at reflux for 6 h.. After cooling to room 
temperature, water (5 mL) was added and the aqueous phase was basified with solid K2CO3 and 
extracted with CHCl3 (3 x 10 mL). The organic phase was dried (MgSO4) and concentrated 
under vacuum to give N-methyl derivatives. 
1-[3-(1,2,5,5-Tetramethyl-4-phenyl-pyrrolidin-2-yl)-prop-2-ynyl]-pyrrolidine (23): 242 mg (78 
%); oil; Rf = 0.28 (CHCl3-Et2O-MeOH 4:1.5:0.5); Anal. calcd. for C21H30N2 (310.48): C 81.24 
 11
%, H 9.74 %, N 9.02 %; found: C 81.17 %, H 9.82 %, N 8.96 %. MS (EI) m/z (rel. int. %): 310 
(M+, 5), 295 (92), 226 (50), 91 (69), 56 (100). 
1-[3-(1,2,5,5-Tetramethyl-4-phenyl-pyrrolidin-2-yl)-prop-2-ynyl]-pyrrolidin-2-one (24): 223 mg 
(69 %); oil; Rf = 0.23 (CHCl3-Et2O 2:1); Anal. calcd. for C21H28N2O (324.47): C 77.74 %, H 
8.70 %, N 8.63 %; found: C 77.63 %, H 8.85 %, N 8.53 %. MS (EI) m/z (rel. int. %): 324 (M+, 
2), 309 (81), 224 (34), 83 (100). 
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